retatrutide triple agonist glp-1 gip glucagon phase 2 results Retatrutide, a (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide for Weight Loss: What

This personalization reduces trial-and-error dosing and accelerates your path to effective therapy

This year, 4.9 million people lost coverage of Zepbound in 2025, and 1.1 million lost coverage of Wegovy, according to GoodRx

While compounded medications are not FDA-approved (meaning they haven't undergone the full FDA approval pathway), the active pharmaceutical ingredients themselvessemaglutide and tirzepatideare FDA-recognized compounds

L.RupprechtL

For extended air travel, USB-powered coolers with dual-mode operation offer the most reliable protection

Gila Peptides provides products strictly for research purposes only